• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于气虚痰浊证型的肠道菌群作为肺腺癌诊断生物标志物的分析

Analysis of Gut Microbiota as a Diagnostic Biomarker for Lung Adenocarcinoma with Qi-Deficiency and Phlegm-Turbid Stagnation.

作者信息

Chen Jiabin, Hu Qinqin, Chai Kequn, Wang Sheng

机构信息

Department of Oncology, Tongde Hospital of Zhejiang Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang 310012, China.

The Second Clinical Medical College, Zhejiang Chinese Medicine University, Hangzhou, Zhejiang 310012, China.

出版信息

Comb Chem High Throughput Screen. 2024 Jun 5. doi: 10.2174/0113862073303081240521083505.

DOI:10.2174/0113862073303081240521083505
PMID:38847243
Abstract

BACKGROUND

In lung adenocarcinoma (LUAD), Qi-deficiency and Phlegm-turbid stagnation (QP) are the most prevalent Traditional Chinese medicine (TCM) syndrome.

METHODS

Herein, we collected 90 fecal samples (Healthy individual (H): 30; other syndrome (O): 30; QP: 30) and explored the composition and diversity of gut microbiota in LUAD patients with QP syndrome using 16s-rRNA sequencing. Then, we identified biomarkers for QP syndrome in LUAD patients with linear discriminant analysis (LDA) effect size (LEfSe) and applied logistic regression analysis to construct a diagnostic model evaluated with the area under the receiver operating characteristic curve (AUC) and validated with data from metagenomics.

RESULTS

The α diversity and β diversity revealed that the microbiota community structure in LUAD patients with QP syndrome was different from that with healthy individuals and LUAD patients with other syndromes. At the phylum level, the QP group had more abundance of Bacteroidetes and less Proteobacteria than the O group. At the genus level, the abundance of 4 genera (Bacteroides, Parabacteroides, Prevotella, and Flavonifractor) was different between the QP group and O group. Moreover, LEfSe indicated that those 4 genera might be the biomarkers for LUAD patients with QP syndrome. Then, we used those 4 genera to develop a diagnostic model. The AUC based on 16s-rRNA sequencing and metagenomics was 0.989 and 1, respectively.

CONCLUSION

A diagnostic model was developed, which would be an available tool for the clinical diagnosis of LUAD with QP syndrome.

摘要

背景

在肺腺癌(LUAD)中,气虚痰浊(QP)是最常见的中医证候。

方法

在此,我们收集了90份粪便样本(健康个体(H):30份;其他证候(O):30份;QP:30份),并使用16s - rRNA测序探索LUAD气虚痰浊证患者肠道微生物群的组成和多样性。然后,我们通过线性判别分析效应大小(LEfSe)确定LUAD患者气虚痰浊证的生物标志物,并应用逻辑回归分析构建诊断模型,用受试者工作特征曲线下面积(AUC)进行评估,并用宏基因组学数据进行验证。

结果

α多样性和β多样性表明,LUAD气虚痰浊证患者的微生物群落结构与健康个体及其他证候的LUAD患者不同。在门水平上,QP组的拟杆菌门丰度高于O组,变形菌门丰度低于O组。在属水平上,QP组和O组之间有4个属(拟杆菌属、副拟杆菌属、普雷沃菌属和黄酮分解菌属)的丰度不同。此外,LEfSe表明这4个属可能是LUAD气虚痰浊证患者的生物标志物。然后,我们用这4个属建立了一个诊断模型。基于16s - rRNA测序和宏基因组学的AUC分别为0.989和1。

结论

建立了一个诊断模型,这将是临床诊断LUAD气虚痰浊证的一个可用工具。

相似文献

1
Analysis of Gut Microbiota as a Diagnostic Biomarker for Lung Adenocarcinoma with Qi-Deficiency and Phlegm-Turbid Stagnation.基于气虚痰浊证型的肠道菌群作为肺腺癌诊断生物标志物的分析
Comb Chem High Throughput Screen. 2024 Jun 5. doi: 10.2174/0113862073303081240521083505.
2
[Relationship Between Different Traditional Chinese Medicine Syndrome Types and Gut Microbiota in Patients With Type 2 Diabetes Mellitus].2型糖尿病患者不同中医证型与肠道微生物群的关系
Sichuan Da Xue Xue Bao Yi Xue Ban. 2025 Mar 20;56(2):389-399. doi: 10.12182/20250360507.
3
Analysis of Gut Microbiota Composition in Lung Adenocarcinoma Patients with TCM Qi-Yin Deficiency.肺腺癌气阴两虚证患者肠道微生物群组成分析
Am J Chin Med. 2021;49(7):1667-1682. doi: 10.1142/S0192415X21500786. Epub 2021 Sep 7.
4
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
5
Integrative metagenomic, transcriptomic, and proteomic analysis reveal the microbiota-host interplay in early-stage lung adenocarcinoma among non-smokers.综合宏基因组学、转录组学和蛋白质组学分析揭示了非吸烟人群早期肺腺癌中微生物组-宿主相互作用。
J Transl Med. 2024 Jul 13;22(1):652. doi: 10.1186/s12967-024-05485-0.
6
Prediction model based on gut microbiota as a non-invasive tool for gastric cancer diagnosis.基于肠道微生物群的预测模型作为胃癌诊断的非侵入性工具。
Appl Microbiol Biotechnol. 2025 Jul 10;109(1):166. doi: 10.1007/s00253-025-13548-5.
7
Gut, vaginal, and urinary microbiota as potential biomarkers of sensitization in women with chronic pelvic pain.肠道、阴道和泌尿微生物群作为慢性盆腔疼痛女性致敏反应的潜在生物标志物。
Am J Obstet Gynecol. 2025 Jan 16. doi: 10.1016/j.ajog.2025.01.013.
8
Characteristics of gut microbiota in patients with asthenozoospermia: a Chinese pilot study.弱精症患者肠道微生物群特征:一项中国初步研究。
BMC Microbiol. 2024 Jan 15;24(1):22. doi: 10.1186/s12866-023-03173-5.
9
Multisite DNA methylation alterations of peripheral blood mononuclear cells serve as novel biomarkers for the diagnosis of AIS/stage I lung adenocarcinoma: a multicenter cohort study.外周血单个核细胞的多部位DNA甲基化改变作为早期侵袭性肺腺癌/Ⅰ期肺腺癌诊断的新型生物标志物:一项多中心队列研究
Int J Surg. 2025 Jan 1;111(1):40-54. doi: 10.1097/JS9.0000000000002101.
10
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.

引用本文的文献

1
Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation.肠道微生物群作为抗癌治疗的新靶点:从作用机制到调控手段
NPJ Biofilms Microbiomes. 2025 Mar 11;11(1):43. doi: 10.1038/s41522-025-00678-x.

本文引用的文献

1
Combining fecal microbiome and metabolomics reveals diagnostic biomarkers for esophageal squamous cell carcinoma.联合粪便微生物组和代谢组学揭示食管鳞癌的诊断生物标志物。
Microbiol Spectr. 2024 May 2;12(5):e0401223. doi: 10.1128/spectrum.04012-23. Epub 2024 Mar 18.
2
Gut Microbiome of Patients With Breast Cancer in Vietnam.越南乳腺癌患者的肠道微生物组。
JCO Glob Oncol. 2024 Feb;10:e2300234. doi: 10.1200/GO.23.00234.
3
A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma.
一项真实世界研究及网络药理学分析表明,埃克替尼联合中药治疗晚期肺腺癌可延缓耐药。
BMC Complement Med Ther. 2023 Nov 21;23(1):422. doi: 10.1186/s12906-023-04213-3.
4
Gut microbiota in human metabolic health and disease.人体肠道微生物群与代谢健康和疾病。
Nat Rev Microbiol. 2021 Jan;19(1):55-71. doi: 10.1038/s41579-020-0433-9. Epub 2020 Sep 4.
5
Traditional Chinese medicine as supportive care for the management of liver cancer: Past, present, and future.中医作为肝癌管理的支持性护理:过去、现在和未来。
Genes Dis. 2019 Nov 2;7(3):370-379. doi: 10.1016/j.gendis.2019.10.016. eCollection 2020 Sep.
6
Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients: A Retrospective Study of 855 Cases.多学科综合中医药治疗晚期非小细胞肺癌 855 例回顾性研究。
Chin J Integr Med. 2021 Jul;27(7):490-495. doi: 10.1007/s11655-020-3428-5. Epub 2020 Sep 2.
7
The role of gut microbiota in cancer treatment: friend or foe?肠道微生物群在癌症治疗中的作用:是敌是友?
Gut. 2020 Oct;69(10):1867-1876. doi: 10.1136/gutjnl-2020-321153. Epub 2020 Aug 5.
8
Enterotoxigenic induces the stemness in colorectal cancer via upregulating histone demethylase JMJD2B.肠产毒性大肠杆菌通过上调组蛋白去甲基化酶 JMJD2B 诱导结直肠癌细胞干性。
Gut Microbes. 2020 Nov 9;12(1):1788900. doi: 10.1080/19490976.2020.1788900. Epub 2020 Jul 20.
9
Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.调节肠道菌群以克服癌症免疫治疗中免疫检查点阻断的耐药性。
Curr Opin Pharmacol. 2020 Oct;54:1-10. doi: 10.1016/j.coph.2020.06.004. Epub 2020 Jun 30.
10
End-to-End Models to Imitate Traditional Chinese Medicine Syndrome Differentiation in Lung Cancer Diagnosis: Model Development and Validation.用于肺癌诊断中模仿中医辨证的端到端模型:模型开发与验证
JMIR Med Inform. 2020 Jun 16;8(6):e17821. doi: 10.2196/17821.